CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) - On June 7, 2021, ADUHELM became the first approved treatment to address a defining pathology of Alzheimer’s disease: targeting the reduction of amyloid plaques in the brain. We believe patients, family members and physicians deserve the facts about the therapy and the process by which it was approved so they may make informed decisions.
- There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
- We are equally proud of the professionalism both our team and the FDA demonstrated during a thorough review process.
- We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab.
- The FDAs decision to approve ADUHELM to treat patients with Alzheimers disease was based on thorough analysis of the data.